A shift to a genotype-first approach {#Sec1}
====================================

Neurodevelopmental disorders (NDs) refer to a complex collection of phenotypes that encompass clinically recognizable disorders such as autism spectrum disorders (ASD), intellectual disability (ID), epilepsy and schizophrenia. The diagnosis of NDs has classically fallen within the clinical realm. The diagnosis of epilepsy is somewhat quantitative, with the frequency, onset and family history of seizure events being considered for classification \[[@CR1]\], whereas the diagnosis of ASD, ID and schizophrenia is historically more complex. The Diagnostic and Statistical Manual of Mental Disorders (DSM, currently DSM-5) is recognized by the US healthcare system as a standard battery of diagnostic criteria for classifying mental disorders. These criteria recognize patients with ASD as those with primarily communication deficits, which can be measured by several standardized tests (e.g., ADOS, ADI-R and BAPQ). In addition to intelligence quotient (IQ) testing, ID is classified by the DSM-5 as involving adaptive functioning impairments in the conceptual, social and practical skills domains. Individuals diagnosed with schizophrenia must present with at least two disease-associated symptoms, which include delusions, hallucinations, disorganized speech and behavior, and social/occupational dysfunction \[[@CR2]\].

Earlier versions of the DSM included phenotypic subtypes for many mental health disorders that have since been eliminated owing to inconsistent diagnoses between clinicians. However, the study of these disorders, ASD and ID in particular, has shown that disease subtypes do exist (such as high-functioning ASD, previously Asperger syndrome) \[[@CR3]\]. Twin studies of ASD, epilepsy and schizophrenia showed that NDs have a strong genetic component (heritability \[h^2^\] = 40--80 % \[[@CR4]--[@CR6]\], h^2^ = 70--88 % \[[@CR7]\], and h^2^ = 64--81 % \[[@CR8], [@CR9]\], respectively). The existence of extensive comorbidity among ND diagnoses has long been recognized; for example, 28 % of individuals who have ID also present with ASD \[[@CR10]\], whereas 26 % present with epilepsy \[[@CR11]\] and 3.7--5.2 % with schizophrenia \[[@CR12]\]. Phenotypic overlap between NDs led to an early hypothesis that common risk genes underlie multiple NDs and, furthermore, that genetic characterization could be a useful diagnostic tool for ND identification and treatment \[[@CR13]\].

Studies of copy number variation and whole-exome or whole-genome sequencing (WES and WGS, respectively) of families have highlighted the importance of rare, de novo gene-disruptive mutations in the genetic etiology of NDs. These studies frequently implicated the same copy number variant, biochemical pathway or even the same gene as an underlying factor of seemingly diverse clinical and etiological outcomes (Table [1](#Tab1){ref-type="table"}). One classic example of this genetic overlap is a microdeletion in chromosome 15q11.3, which has been associated with multiple NDs (ASD, ID, epilepsy and schizophrenia) \[[@CR14]\]. At the single-gene level, exome sequencing studies have highlighted that specific loci, such as *SYNGAP1*, *ARID1B* and *ADNP*, are likely to contribute to both ASD and ID, whereas mutations in genes such as *STXBP1* and *WDR45* might contribute to ID and epilepsy but not ASD (Table [1](#Tab1){ref-type="table"}). Recognition of this genetic overlap and the subtlety of the clinical diagnoses of NDs have led to the development of a so-called genotype-first approach, in which patients with a common genotype (i.e., a disruptive variation in the same gene) are collected for deep clinical phenotyping to define the specific disease attributes associated with each candidate ND risk gene \[[@CR15]\]. This approach contrasts with phenotype-driven approaches, in which patients are collected on the basis of a shared clinical presentation and used to identify candidate risk genes post hoc.Table 1Top de novo genes associated with ND riskGeneASD^b^ID/DD^c^EP^d^SZ^e^Total casesControl counts^f^*p* valueOR (95 % CI)Pathway^g^*SYNGAP1* ^a^79001611.45E-1288.0 (13.7--3613.0)S*SCN2A* ^a^67011411.34E-1186.7 (13.2--3587.4)S*ARID1B* ^a^511001659.29E-1017.6 (6.2--61.5)C, T, W*ANKRD11* ^a^28001012.63E-0861.9 (8.8--2644.0)D*CHD8* ^a^120011343.52E-0817.9 (5.5--75.2)C, T, W*ADNP* ^a^5400921.99E-0624.7 (5.1--234.2)T*DYRK1A* ^a^5300812.46E-0644.0 (5.9--1929.7)K, D*CTNNB1* ^a^1600711.42E-0538.5 (4.9--1716.8)T, W*CHD2* ^a^5210833.36E-0514.7 (3.5--85.7)C, T*STXBP1*0510618.12E-0532.9 (4.0--1503.0)S*POGZ*3201621.58E-0418.5 (3.3--187.6)R*MED13L*2400622.82E-0416.5 (2.9--166.8)T, W*TRIP12*2200405.63E-04∞ (3.6--∞)U*KMT2A*2400649.24E-049.3 (2.2--44.7)C*EP300*1400532.03E-0310.3 (2.0--66.5)C, T, W*GRIN2B*3100412.47E-0322.0 (2.2-1075.1)S*DDX3X* ^a^1200302.70E-03∞ (2.6--∞)T, W*SUV420H1*3000302.70E-03∞ (2.6--∞)C, T*WDR45*0210302.70E-03∞ (2.6--∞)A*CHAMP1* ^a^0300303.66E-03∞ (2.3--∞)R*SCN1A* ^a^0040426.50E-0311.0 (1.6--121.5)S*WAC* ^a^2200426.50E-0311.0 (1.6--121.5)C, T*AHDC1* ^a^1200319.68E-0318.5 (1.5--967.5)Db*SATB2*0300319.68E-0318.5 (1.5--967.5)C, TAll counts represent de novo mutations that are likely to be gene-disruptive, including frameshift, splice and nonsense mutations ^a^Gene also identified through genotype-first approaches. ^b^5001--5922 individuals with ASD were screened depending on the gene. ASD data have been previously published \[[@CR19], [@CR23]--[@CR28]\]. ^c^1284 individuals with ID/DD were screened. ID/DD data have been previously published \[[@CR29]--[@CR31]\]. ^d^274 individuals with EP were screened. EP data have been previously published \[[@CR32], [@CR33]\]. ^e^785 individuals with SZ were screened. SZ data have been previously published \[[@CR34]--[@CR36]\]. ^f^Data from 45,376 control individuals were obtained from the ExAC database. The disruptive mutations counted here represent unaffected population control individuals and individuals with diseases other than neuropsychiatric disorders \[[@CR37]\]. These data were used to calculate the Fisher's exact test *p* value. Only disruptive (frameshift, splice, nonsense) variants were scored in cases and controls. ^g^Pathway annotations determined using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 \[[@CR57], [@CR58]\]. *A* Autophagy, *ASD* Autism spectrum disorders, *C* Chromatin remodeling, *CI* Confidence interval, *D* Broad development, *Db* DNA binding, *DD* Developmental delay, *EP* Epilepsy, *ID* Intellectual disability, *K* Kinase, *OR* Odds ratio, *R* Replication, *S* Synapse function, *SZ* Schizophrenia, *T* Gene transcription, *U* E3 ubiquitin-protein ligase, *W* Wnt/β-catenin signaling

The goal of this Opinion is to review advances in the discovery of candidate genes based on next-generation sequencing of patients and the impact of these advances on refining specific subtypes of ND. Linking genotypes to deep clinical phenotypes (including information obtained through application of best-practice DSM-5 criteria, clinical dysmorphology assessment, analysis of family histories and electroencephalography) is providing important insight into ND risk gene models \[[@CR16]--[@CR18]\]. We propose that grouping patients on the basis of a shared genetic etiology is a critical first step in tailoring improved therapeutics to a defined subset of patients.

Gene discovery and phenotypic refinement {#Sec2}
========================================

The affordable application of next-generation sequencing in the clinical and research arenas has rapidly increased our understanding of the genetic variation that underlies NDs. Exome and targeted sequencing studies of patients with ND have revealed dozens of new genes emerging as high-risk candidate loci in recent years (Table [2](#Tab2){ref-type="table"}). WES sequencing of patients with ASD led to estimates that 500--1000 genes contribute to disease etiology \[[@CR19]\], whereas in ID this number is greater than 1000 \[[@CR20]\]. Epilepsy and schizophrenia are thought to be less genetically heterogeneous, involving approximately 500 \[[@CR21]\] and 600 \[[@CR22]\] genes, respectively. Although associations between certain gene variants and ND risk have been consistently replicated (such as de novo disruptive mutations in *CHD8*, *ADNP* and *DYRK1A* \[[@CR19]\] among ASD and ID simplex families), hundreds of ND risk genes remain undiscovered or have not been associated with NDs with sufficient statistical significance owing to ultra-low mutation frequencies in the patient population.Table 2Genes linked to NDs identified through genotype-first approachesGeneLocusPhenotypeReferences*ADNP*20q13.13ASD, ID, loss of expressive language, facial dysmorphisms\[[@CR17]\]*AHDC1*1p35.3ID/DD, hypotonia, mild dysmorphic facial features, sleep apnea\[[@CR59]\]*ANKRD11*16q24.3KGB syndrome: macrodontia of central upper incisors, dental anomalies, facial dysmorphism, ASD, hyperactivity, hearing loss, heart defects\[[@CR60], [@CR61]\]*ARID1A*1p36.11Coffin--Siris syndrome with sucking/feeding difficulties, distinct faces including some facial coarseness with short nose, gastrointestinal complications, some hearing and visual impairments, prone to infection, hypotonia, structural CNS abnormalities, mild to severe ID/DD, behavioral abnormalities\[[@CR62], [@CR63]\]*ARID1B*6q25.3Highly variable Coffin--Siris syndrome with hypoplasia of the corpus callosum, hearing problems\[[@CR62], [@CR64]\]*ARID2*12q12ID/DD, ADHD, short stature, dysmorphic facial features, Wormian bones\[[@CR65]\]*AUTS2*7q11.22ID, ASD, short stature, microcephaly, cerebral palsy, facial dysmorphism\[[@CR66]\]*BRWD3*Xq21.1Mild to moderate ID, speech delay, behavioral disturbances, macrocephaly, dysmorphic facial features, skeletal symptoms\[[@CR67]\]*CHAMP1*13q34ID, speech impairment, motor DD, muscular hypotonia, dysmorphic features\[[@CR68]\]*CHD2*15q26.1Archetypal generalized photosensitive epilepsy syndrome, eyelid myoclonia with absences, ID, ± ASD\[[@CR38], [@CR69]--[@CR71]\]*CHD8*14q11.2ASD, macrocephaly, distinct faces, gastrointestinal complaint, sleep disturbance\[[@CR16]\]*CTNNB1*3p22.1ID, microcephaly, limited speech and progressive spasticity\[[@CR72], [@CR73]\]*CUL4B*Xq24X-linked ID, cerebral malformations, seizures, tremors, gait abnormalities, behavioral problems, macrocephaly, short stature, obesity, hypogonadotropic hypogonadism, variable dysmorphic features\[[@CR74]\]*DDX3X*Xp11.4ID, hypotonia, movements disorders, behavior problems, corpus callosum hypoplasia, EP\[[@CR53]\]*DEAF1*11p15.5Severe ID, severely affected speech development, behavioral problems\[[@CR75]\]*DYNC1H1*14q32.31Severe ID, neuronal migration defects, broad phenotypic spectrum\[[@CR76]\]*DYRK1A*21q22.13DD, ASD, microcephaly, late-onset EP, severe anxiety\[[@CR18]\]*GATAD2B*1q21.3Severe ID, childhood hypotonia, limited speech, tubular nose with broad nasal tip, short philtrum, sparse hair and strabismus\[[@CR77]\]*GRIN2A*16p13.2Epilepsy--aphasia spectrum disorders\[[@CR78]\]*HDAC8*Xq13.1ID, behavioral problems (including ASD in some patients), delayed anterior fontanelle closure, ocular hypertelorism, hooding of the eyelids, broad nose and dental anomalies\[[@CR79]\]*HIVEP2*6q24.2ID, structural brain anomalies, hypotonia, mild dysmorphic features\[[@CR80]\]*KCNH1*1q32.2Severe ID, neonatal hypotonia, hypertelorism, broad nasal tip, wide mouth, nail aplasia or hypoplasia, proximal implanted and long thumb and long great toes\[[@CR81]\]*KCNT1*9q34.3Highly pleiotropic, including nocturnal frontal lobe EP, malignant migrating focal seizures of infancy, Ohtahara syndrome, multifocal EP, cardiac disturbances\[[@CR82]\]*KDM5C*Xp11.22X-linked ID\[[@CR83]\]*KIAA2022*Xq13.3X-linked ID, ASD features, strabismus\[[@CR84]\]*KIF1A*2q37.3Cognitive impairment, variable cerebellar atrophy, spastic paraparesis, optic nerve atrophy, peripheral neuropathy, EP\[[@CR85]\]*KIF4A*Xq13.1ID, EP\[[@CR86]\]*KIF5C*2q23.1Severe ID, EP, microcephaly, cortical malformation\[[@CR86]\]*MAN1B1*9q34.3ID, delayed motor and speech development, obesity, macrocephaly\[[@CR87]\]*MLL2 (KMT2D)*12q13.12Severe form of Kabuki syndrome with distinct facial features (large dysplastic ears, arched eyebrows with sparse lateral third, blue sclerae, flat nasal tip with a broad nasal root, a thin upper lip and a full lower lip)\[[@CR88]\]*MYT1L*2p25.3Syndromic ID and/or central obesity\[[@CR89]\]*NRXN1*2p16.3Predisposition for idiopathic generalized EP syndromes\[[@CR90]\]*PGAP1*2q33.1ID, cerebral visual impairment\[[@CR91]\]*PHF21A*11p11.2Potocki--Shaffer syndrome associated with ID and craniofacial anomalies\[[@CR92]\]*PPP2R1A*19q13.41ID, hypotonia, EP, frontal bossing, mild hypertelorism, downslanting palpebral fissures\[[@CR93]\]*PPP2R5D*6p21.1ID, ASD, macrocephaly, hypotonia, seizures, dysmorphic features\[[@CR93], [@CR94]\]*SCN1A*2q24.3EP with febrile seizures plus generalized epilepsy with febrile seizure plus (GEFS+), epilepsy--aphasia\[[@CR38]\]*SCN2A*2q24.3ID/DD, seizure disorders (epileptic encephalopathy); previously implicated in ASD and SZ\[[@CR38], [@CR95], [@CR96]\]*SCN8A*12q13.13Early-infantile epileptic encephalopathy type 13, ± ID, hypotonia, movement disorders\[[@CR38], [@CR97], [@CR98]\]*SETBP1*18q12.3ID, loss of expression language\[[@CR99]\]*SETD5*3p25.3ID, facial dysmorphism\[[@CR100]\]*SLC6A1*3p25.3Spontaneous spike-wave discharges associated with epileptic encephalopathy\[[@CR101]\]*SMARCA4*19p13.2Coffin--Siris syndrome with moderately coarse craniofacial features and behavioral abnormalities\[[@CR62], [@CR63]\]*SMARCB1*22q11.23Coffin--Siris syndrome with severe neurodevelopmental deficiencies, including severe ID, seizures, CNS structural abnormalities, no expressive words, scoliosis\[[@CR62], [@CR63]\]*SMARCE1*17q21.2Coffin--Siris syndrome with severe to moderate ID and a wide spectrum of manifestations\[[@CR63]\]*SMC3*10q25.2Cornelia de Lange syndrome with postnatal microcephaly, moderately distinctive craniofacial appearance, mild prenatal growth retardation that worsens in childhood, some congenital heart defects, absence of limb deficiencies\[[@CR102]\]*SRCAP*16p11.2Floating--Harbor syndrome: short stature with delayed bone age, deficits in expressive language, distinctive faces\[[@CR103]\]*SYNGAP1*6p21.32Multiple seizure types, early DD, regression, ID\[[@CR38]\]*USP9X*Xp11.4X-linked ID\[[@CR104]\]*WAC*10p11.23ID/DD, hypotonia, behavioral problems, eye abnormalities, constipation, feeding difficulties, seizures, sleep problems, dysmorphic features\[[@CR105]\]*ZMYND11*10p15.3ID, ASD, aggression, complex neuropsychiatric features\[[@CR99]\]*ADHD* Attention deficit hyperactivity disorder, *ASD* Autism spectrum disorders, *CNS* Central nervous system, *DD* Developmental delay, *EP* Epilepsy, *ID* Intellectual disability, *SZ* Schizophrenia

We combined the results of multiple published WES, WGS and targeted sequencing studies including 5001--5922 individuals with ASD (single gene denominators varied owing to the variety of WES, WGS and targeted sequencing approaches used) \[[@CR19], [@CR23]--[@CR28]\], 1284 individuals with ID \[[@CR29]--[@CR31]\], 274 individuals with epilepsy \[[@CR32], [@CR33]\] and 785 individuals with schizophrenia \[[@CR34]--[@CR36]\] to look for genetic overlap between these NDs. Using this large dataset (over 7000 individuals/families), we identified the top 25 genes that show an excess of disruptive (frameshift, splice, nonsense) gene mutations in disease cases when these individuals are compared with 45,376 controls drawn from the ExAC database \[[@CR37]\], where neuropsychiatric cases were masked before analysis (Table [1](#Tab1){ref-type="table"}). Although the number of individuals represented in each disease study differs and several genes reach only nominal significance, the identified genes clearly converge on common biochemical and neurodevelopmental pathways, such as synaptic function, chromatin remodeling, gene transcription and Wnt/β-catenin signaling. Importantly, significance thresholds are likely to be highly conservative, as the ND studies that were included in the analysis only considered confirmed de novo events, whereas the ExAC database variants have not been filtered for population frequency and inheritance status is unknown. Using our large dataset of de novo mutations associated with ND we can apply a recurrent de novo simulation model which considers the size and evolutionary conservation of individual genes to calculate the likelihood of observing a number of de novo mutations in any given ND-associated gene \[[@CR23]\]. In some cases we find that genes that were not statistically significant for overall disruptive mutational burden after Bonferroni correction (*p* \< 10-6) of the Fisher's exact test *p* value are indeed significant for recurrent de novo mutation burden --- such as *GRIN2B*, which has a de novo *p* value of 0.001 after correction. Therefore, although some genes (e.g., *GRIN2B*) reach only nominal significance for an overall increased burden in disruptive mutations in ND cases compared with unaffected controls, based on a de novo model they may prove to be bona fide ND risk genes.

The discovery of recurrently mutated genes has been used to successfully identify additional patients with disruptive mutations in these risk genes who, when collectively phenotyped, define new syndromic and sub-syndromic forms of ND \[[@CR16]--[@CR18]\]. These efforts have proceeded in parallel with the coordination of clinical exome sequencing of patients, which has led to the identification of dozens of individuals with the same type of rare molecular defect (Table [2](#Tab2){ref-type="table"}). This coordination led to the emergence of refined patient checklists that enable a systematic reassessment of pediatric, neuroimaging, neurobehavioral and morphological features \[[@CR15]\]. Such genotype--phenotype studies have shown that individuals sharing a genetic etiology have more features in common than those they share with the general ND population. These observations have led to the description of both genetic and clinical subtypes of ND, some of which may be considered syndromic by clinicians.

Many of the top ND risk genes identified in our analysis are correlated with an observable phenotype that may have been predicted based on our analysis (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). For example, *CHD8* is an ASD-associated gene linked with macrocephaly and gastrointestinal dysfunction \[[@CR16]\], whereas *ADNP* mutations are associated with ASD and the complete loss of expressive language \[[@CR17]\]. Some genes seem to be predominantly associated with ID (e.g., *ARID1B*, *ANKRD11*, *CTNNB1*, *STXBP1* and *CHAMP1*). *SCN1A* mutations have been primarily observed in epilepsy \[[@CR38]\]. Other genes are strongly associated with epilepsy and ID (e.g., *CHD2* and *DYRK1A*), often with very specific clinical manifestations (e.g., microcephaly and late-onset epilepsy in the case of patients with *DYRK1A* variants \[[@CR18]\]. The potential contribution of some of these ND genes (e.g., *SCN2A*, *CHD8* and *POGZ*; Table [1](#Tab1){ref-type="table"}) to adult neuropsychiatric diseases, such as schizophrenia, is intriguing, although statistical significance supporting these associations is still lacking. The existence of such associations would suggest that mutations in these genes have broad phenotypic effects or variable expressivity that manifests as ND at different developmental stages. It will be important to identify families in which gene-disruptive mutations in these genes are segregated in order to explore phenotypic differences among the familial carriers.

Molecular pathways and therapeutic potential {#Sec3}
============================================

Beyond genetic subtypes, network-based approaches that more globally predict the effects of ND risk genes on molecular pathways have repeatedly shown an enrichment for synapse function and gene transcription/chromatin remodeling \[[@CR19], [@CR39]\]. Although these pathways remain the most statistically significant pathways found among ND datasets, other pathways have been identified, including interaction with SNARE proteins and vesicular transport pathways in epilepsy (*p* \< 0.03) and FMRP targets in ASD, ID and epilepsy (*p* \< 0.00001) \[[@CR39]\]. Given the extensive locus heterogeneity of these diseases, pathway-defined 'molecular subtypes' are likely to become the ultimate target for behavioral and pharmacological therapeutics.

Each of these large functional networks can be further subdivided into smaller pathways, such as long-term potentiation, calcium signaling, postsynaptic density and synapse structure in the case of synaptic function, in which enrichment is driven by signals from de novo mutations in genes such as *SYNGAP1*, *SCN2A*, *STXBP1*, *GRIN2B* and *SCN1A* (Table [1](#Tab1){ref-type="table"}). *SCN2A* and *SCN1A* are members of the same gene family of voltage-gated sodium channels that are responsible for the generation and propagation of action potentials and have been associated with seizure phenotypes in animal models \[[@CR38]\]. Although SCN1A de novo mutations seem to be specific to epilepsy \[[@CR38]\], we observe SCN2A de novo mutations in both ASD and ID (Table [1](#Tab1){ref-type="table"}), which suggests that long-term potentiation has a role in multiple forms of ND. It is important to note, however, that we are classifying mutations using the primary clinical diagnosis under which each patient's cohort was originally ascertained. As a large phenotypic overlap exists between NDs, we could reasonably hypothesize, for example, that patients with ASD or ID and an *SCN2A* mutation could also manifest with seizure phenotypes.

An enrichment for synapse function in ND has been observed primarily in a subset of patients with ID, epilepsy and schizophrenia \[[@CR39]\]. Many antipsychotic and psychotropic compounds have been developed to modulate synaptic function to treat comorbid conditions (hyperactivity, depression, anxiety, aggression and seizures) often associated with NDs. These medications may be used more effectively when applied to patients with a molecular perturbation in the relevant gene or pathway. For example, benzodiazepines (e.g., clonazepam) are a class of drugs that increase GABA~A~ receptor activity and thus contribute to the inhibition of action potentials in the central nervous system, which are often overactive in seizure conditions \[[@CR40]\]. Efforts are currently underway to specifically tailor benzodiazepines to treat patients with mutations in *SCN2A* and *SCN1A* \[[@CR41], [@CR42]\] (Dr. Raphael Bernier, personal communication). Clemizole, a compound approved by the US Food and Drug Administration, has been shown to mitigate some of the convulsive behavior of *Scn1a* mutant zebrafish \[[@CR43]\]. *Scn2a* mutant mice are being used in the development of other similar sodium-channel-inhibiting compounds, including GS967 \[[@CR44]\].

Studies of simplex ASD and ID families have highlighted an enrichment for gene-disruptive mutations in transcription and chromatin remodeling pathways (e.g., SWI/SNF complex, Wnt/β-catenin and mTOR) \[[@CR19], [@CR39], [@CR45]\]. Wnt/β-catenin and mTOR pathways are involved in gene transcription, cell growth, migration and patterning during embryonic development \[[@CR46], [@CR47]\]. These pathways are closely linked to the SWI/SNF nucleosome remodeling complex, which is involved in the regulation of gene expression and is thought to have a role in neural specification \[[@CR48]\]. Understanding the molecular biology of these pathways may reveal additional therapeutic targets. *ADNP*, for example, is a transcription factor that interacts directly with the SWI/SNF complex. Davunetide, a derivative octapeptide of *ADNP*, has been shown to ameliorate some of the cognitive deficits in animal models with *ADNP* mutations, which is a promising line of therapeutic research for ADNP patients with similar defects \[[@CR49]\]. Some ND-associated genes (Table [1](#Tab1){ref-type="table"}) are simultaneously involved in chromatin remodeling and transcription, such as *ARID1B* \[[@CR50]\] and *CHD8* \[[@CR51]\], which have been linked to the SWI/SNF and Wnt/β-catenin signaling pathways \[[@CR16], [@CR50]\] (Table [1](#Tab1){ref-type="table"}) and are known to be important for proliferation of neural precursors \[[@CR23], [@CR39], [@CR52]\].The study of genetic subtypes of ND associated with the Wnt/β-catenin pathway --- specifically *DDX3X* and *CHD8* --- suggests that mutations in this pathway are important in the very early stages of development \[[@CR16], [@CR53]\]. Importantly, mutations in *DDX3X* account for a large percentage of unexplained ID in female individuals (1--3 %) \[[@CR53]\], which was overlooked in studies of ASD alone \[[@CR54]\] (Table [1](#Tab1){ref-type="table"}). The Wnt/β-catenin pathway is commonly dysregulated in cancer; over 40 compounds have been shown to modulate Wnt/β-catenin pathway activity in model systems or in vivo that might be considered for use in specific genetic subtypes of ND in the future \[[@CR55]\].

Mutations in the mTOR pathway involving genes such as *TSC* and *PTEN* have also been implicated in tumorigenesis and ND owing to their role in transcription and cell growth \[[@CR47]\]. Rapalogues, including sirolimus (rapamycin) and everolimus, which inhibit TORC1 and are commonly used to treat cancer, are currently under investigation to assess whether they can improve ASD-related symptoms in patients with *TSC* mutations \[[@CR56]\]. Similar disease-modifying therapies might be useful to treat patients with other genetic subtypes of ND in which mTOR function is abrogated. However, the use of drugs targeting both Wnt/β-catenin and mTOR pathways will need to be carefully considered and fine-tuned for use in NDs to avoid adverse side effects. Although killing healthy cells in adults is an acceptable consequence of cancer treatment, this is not the case during pediatric brain development.

Conclusions {#Sec4}
===========

The success of the genotype-first approach for subtyping NDs can be primarily attributed to technological advances that make WES and targeted sequencing fast and cost-effective. ND candidate gene discovery can be maximized by combining many datasets from overlapping conditions (e.g., ASD, ID, epilepsy and schizophrenia) to (1) increase the genetic evidence supporting individual ND risk gene models, (2) build stronger molecular interaction networks that implicate specific pathways in disease biology and (3) assess the robustness of genotype--phenotype links. Beyond providing a potential genetic explanation for disease to families, our understanding of the biological pathways that are disrupted by specific variants is leading to improved assessment of disease risk in families and to the prospect of tailored treatments for patients with these debilitating diseases.
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